Program
C-CAR168
Its studies are mostly in Lupus Nephritis · Multiple Sclerosis, Chronic Progressive · Scleroderma, Systemic, led by AbelZeta.
Furthest: phase 2, since Mar 26, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbelZeta | 43 open or running | phase 2since Mar 26, 2025 | Mar 26, 2025 | Dec 2028phase 1 · NCT07854483 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 26, 2025First study: phase 2 study in Lupus NephritisFirst studyNCT06935474 · United States
- Jul 16, 2026Phase 2 study in Lupus NephritisNCT07729826 · 50 planned
- Sep 8, 2026Phase 2 study in Multiple SclerosisNCT07825389 · 119 planned · United States
- Sep 27, 2026Phase 1 study in Scleroderma, SystemicNCT07854483 · 12 planned · United States
Ahead
- Dec 2028Primary completion: phase 1 study in Scleroderma, SystemicNCT07854483
- Dec 31, 2028Primary completion: phase 2 study in Lupus NephritisNCT07729826
- Feb 2030Primary completion: phase 2 study in Multiple SclerosisNCT07825389
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07854483Scleroderma, Systemic · United States | 1 | Not yet recruiting | Dec 2028 | 12 |
| NCT07825389Multiple Sclerosis · United States | 2 | Not yet recruiting | Feb 2030 | 119 |
| NCT07729826Lupus Nephritis | 2 | Not yet recruiting | Dec 31, 2028 | 50 |
| NCT06935474Lupus Nephritis · United States | 2 | Withdrawn | May 2029 | 0 |
How it is read
Names in the registry
- “C-CAR168”, 4 entries
Conditions, from the studies’ own filings
- Lupus Nephritis, 2 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.